Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    HomeMedication GuideMethylprednisolone Safety
    Systemic corticosteroid

    Methylprednisolone: What to Know Before You Take It

    Also sold as Medrol

    What Methylprednisolone Is Used For

    INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

    Warnings

    WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. 1 These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. 2 There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Usage in pregnancy: Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism. Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids. The use of methylprednisolone tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

    Contraindications

    CONTRAINDICATIONS Systemic fungal infections and known hypersensitivity to components.

    Methylprednisolone Drug Interactions (8)

    Methylprednisolone + Aspirin
    Methylprednisolone may increase the clearance of chronic high dose aspirin.
    Moderate interaction
    Methylprednisolone + Itraconazole
    Budesonide (inhalation) a Budesonide (non­-­­­inhalation) Ciclesonide (inhalation) Cyclosporine (IV) a Cyclosporine (non-IV) Dexamethasone a Fluticasone (inhalation) a Fluticasone (nasal)Methylprednisolone a Tacrolimus (IV) a Tacrolimus (oral) Monitor for adverse reactions.
    Moderate interaction
    Methylprednisolone + Phenytoin
    Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response.
    Moderate interaction
    Methylprednisolone + Rifampin
    Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response.
    Moderate interaction
    Methylprednisolone + Tacrolimus
    Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations.
    Moderate interaction
    Methylprednisolone + Clarithromycin
    Other Drugs Metabolized by CYP3A: Alfentanil Bromocriptine Cilostazol Methylprednisolone Vinblastine Phenobarbital St.
    Minor interaction
    Methylprednisolone + Hydrocortisone
    Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium.
    Minor interaction
    Methylprednisolone + Ketoconazole
    Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
    Minor interaction

    Check Methylprednisolone against your full medication list in our free Interaction Checker

    Most-Reported Side Effects

    Based on 167,055 reports in the FDA Adverse Event Reporting System (FAERS). Reports do not prove the drug caused the effect.

    off label use25,038drug ineffective18,289fatigue10,285pain9,812nausea9,363headache9,336pyrexia9,015dyspnoea8,624arthralgia8,152pneumonia8,055diarrhoea7,933condition aggravated7,432

    Explore full Methylprednisolone safety data in our free FDA Safety Explorer

    FDA Recalls (showing 12 of 14)

    Class IIOngoingJan 15, 2026

    Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

    Recalling firm: Greenstone Llc

    Class IIOngoingApr 25, 2024

    Presence of Particulate Matter: Potential for black particulates in the drug product.

    Recalling firm: Sagent Pharmaceuticals

    Class IIOngoingFeb 20, 2024

    Failed Dissolution Specifications

    Recalling firm: Eugia US LLC

    Class IITerminatedApr 13, 2022

    cGMP deviations: Temperature abuse

    Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office

    Class IITerminatedApr 13, 2022

    cGMP deviations: Temperature abuse

    Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office

    Class IIITerminatedJan 14, 2020

    Labeling: Incorrect Instructions: Vial label incorrectly instructs healthcare professional to reconstitute product with 16 mL rather than the correct volume of 8 mL of Bacteriostatic Water for Injection with Benzyl Alcohol.

    Recalling firm: Hikma Pharmaceuticals USA Inc.

    Class IITerminatedMay 6, 2019

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    Recalling firm: Zydus Pharmaceuticals USA Inc

    Class IITerminatedMay 6, 2019

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    Recalling firm: Zydus Pharmaceuticals USA Inc

    Class IITerminatedMay 6, 2019

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    Recalling firm: Zydus Pharmaceuticals USA Inc

    Class IITerminatedMay 6, 2019

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    Recalling firm: Zydus Pharmaceuticals USA Inc

    Class IITerminatedMay 6, 2019

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    Recalling firm: Zydus Pharmaceuticals USA Inc

    Class IIITerminatedOct 10, 2014

    Subpotent; 6 month stability time point

    Recalling firm: American Health Packaging

    This information is educational — not medical advice.

    This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.

    Considering Methylprednisolone? Talk to a Provider First

    Our board-certified providers can review whether Methylprednisolone is right for you, check it against your current medications, and prescribe online when appropriate.